Tuesday, September 18, 2018
Company News: Page (1) of 1 - 07/03/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Intravenous (IV) Iron Drugs 2018: Global Strategic Business Outlook to 2024 - Expanding Pool of ESRD and CKD Patients: The Major Growth Driver

(July 03, 2018)

Dublin, July 03, 2018 (GLOBE NEWSWIRE) -- The "Intravenous (IV) Iron Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Thousand.

The report profiles 21 companies including many key and niche players such as:

  • Allergan Plc. (Ireland)
  • AMAG Pharmaceuticals, Inc. (USA)
  • Daiichi Sankyo, Inc. (USA)
  • Luitpold Pharmaceuticals, Inc. (USA)
  • American Regent, Inc. (USA)
  • Pharmacosmos A/S (Denmark)
  • Sanofi US (USA)
  • Vifor Pharma Ltd. (Switzerland)
  • Vifor Fresenius Medical Care Renal Pharma (Switzerland)

Key Topics Covered

Iron Deficiency Anemia (IDA)
An Overview
Intravenous (IV) Iron Drugs Market
A Quick Primer
US and Europe Dominate IV Iron Market
The Fastest Growing Market
Leading Intravenous Iron Drugs Globally
Leading IV Iron Drugs Available in the Market
Leading Intravenous Iron Drugs: In a Nutshell
The Leading Intravenous Iron Drug Globally
Looses Ground to Ferinject
Feraheme Obtains Broader Label Approval
Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA
Gluconate (Ferrlecit® and Nulecit)
Global Market Leaders

Expanding Pool of ESRD and CKD Patients
The Major Growth Driver for Intravenous (IV) Iron Drugs
ESRD Prevalence Statistics: An Opportunity Indicator
Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
Dialysis Patients
A Major Market for Intravenous Iron Supplements
Ageing Population Drives Demand for IV Iron Drugs
Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
Comparison of Ferrous Salts with IV Iron Therapy
Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
Anemia in Heart Failure
A Market with Huge Potential
Chemotherapy Induced Anemia to Promote IV Iron Supplements
Correction of IDA in Pregnancy Signals Opportunities
Women’s Health
A Key Growth Opportunity
Perioperative and Postoperative Anemia
A Niche Market Beckons
Adverse Reactions of IV Iron Preparations Raise Concerns
Dosing Limitations Plague IV Iron Market
Select Therapeutic Areas and the Required Iron Doses

Increasing Trend towards Bundled Reimbursements
A Glimpse of Regulations in the US and Europe
Comparison of Approved Indications and Safety Warnings for Select FDA Approved IV Iron Drugs
Coverage of IV Iron and ESA in the Reimbursement Packages of Dialysis Services across Belgium, Germany, Netherlands, the UK, France, the US and Ontario, Canada


AMAG to Expand Feraheme® Label
Pharmacosmos and Laboratoire Aguettant to Commercialize Monover® in France
Pharmacosmos and Pfizer to Commercialize Monover® in Brazil
Rockwell Medical Announces Data Presentation on Triferic Intravenous (IV) Administration
Nippon Shinyaku and Pharmacosmos to Develop and commercialize Monofer® in Japan
Lupin Announces the Launch of Novel Injectable Iron Formulation in India
Pharmacosmos and Pfizer to Commercialize Monofer® in Canada

Allergan Plc. (Ireland)
AMAG Pharmaceuticals, Inc. (USA)
Daiichi Sankyo, Inc. (USA)
Luitpold Pharmaceuticals, Inc. (USA)
American Regent, Inc. (USA)
Pharmacosmos A/S (Denmark)
Sanofi US (USA)
Vifor Pharma Ltd. (Switzerland)
Vifor Fresenius Medical Care Renal Pharma (Switzerland)


Total Companies Profiled: 21 (including Divisions/Subsidiaries 22)

The United States ((5)
Japan (2)
Europe (7)
- France (1)
- Germany (1)
- The United Kingdom (1)
- Rest of Europe (4)
Asia-Pacific (Excluding Japan) (8)

For more information about this report visit https://www.researchandmarkets.com/research/b9925f/intravenous_iv?w=12

CONTACT: CONTACT: ResearchAndMarkets.com         Laura Wood, Senior Manager         [email protected]         For E.S.T Office Hours Call 1-917-300-0470         For U.S./CAN Toll Free Call 1-800-526-8630         For GMT Office Hours Call +353-1-416-8900         Related Topics: Infusions and Injectables , Hematological Drugs 

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Brain Ischemia Market Analysis 2018-2023 | Increased Prevalence Rate with Topmost Players ThromboGenics, Vernalis, Neurotec Pharma, Covidien and Others - Asserts MRFR
  • IV Infusion Pump Accessories Market is poised to register a CAGR of 4.5% by 2025 – Persistence Market Research
  • Effie Chow Qigong Healing System Available On Mediterranean Celebrity Cruise Line Says Sharon Kleyne & Rose Hong
  • The Methuselah Foundation Successfully Closes its Boutique Venture Fund, the Methuselah Fund, Focused on Companies That Can Extend the Healthy Human Lifespan
  • Report on CPH by Research Dynamics: Investor Day update

  • Sequana Medical reports positive data on use of the alfapump® in malignant ascites patients at the International Gynecologic Cancer Society
  • Astellas Promotes Geoff Towle to Vice President of Oncology Marketing at Astellas US
  • Chardan Advises NovellusDX in Cross-Border Biotech Merger
  • Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company
  • Chemotherapy-Induced Nausea & Vomiting (CINV) Treatment - Worldwide Markets to 2026: A $3.62 Billion Opportunity

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines